A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Conditions: Type 2 Diabetes Mellitus Interventions: Drug: Cagrilintide; Drug: Semaglutide; Drug: Placebo cagrilintide; Drug: Placebo semaglutide Sponsors: Novo Nordisk A/S Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Conditions: Type2diabetes; PreDiabetes; Renal Failure Interventions: Drug: Dapagliflozin (Forxiga®); Drug: Placebo matching Dapaglifolzin; Behavioral: Lifestyle Intervention Sponsors: University Hospital Tuebingen; German Federal Ministry of Education and Research; German Center for Diabetes Research; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
The Effects and Mechanism of SGLT2 Inhibitors in Stage B of Heart Failure With Hypertension
Conditions: Heart Failure; Hypertension; Left Ventricle Remodeling; Left Atrial Dilatation Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Sponsor: China National Center for Cardiovascular Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Conditions: Type2diabetes; PreDiabetes; Renal Failure Interventions: Drug: Dapagliflozin (Forxiga®); Drug: Placebo matching Dapaglifolzin; Behavioral: Lifestyle Intervention Sponsors: University Hospital Tuebingen; German Federal Ministry of Education and Research; German Center for Diabetes Research; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
The Effects and Mechanism of SGLT2 Inhibitors in Stage B of Heart Failure With Hypertension
Conditions: Heart Failure; Hypertension; Left Ventricle Remodeling; Left Atrial Dilatation Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Sponsor: China National Center for Cardiovascular Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Conditions: Type2diabetes; PreDiabetes; Renal Failure Interventions: Drug: Dapagliflozin (Forxiga®); Drug: Placebo matching Dapaglifolzin; Behavioral: Lifestyle Intervention Sponsors: University Hospital Tuebingen; German Federal Ministry of Education and Research; German Center for Diabetes Research; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
The Effects and Mechanism of SGLT2 Inhibitors in Stage B of Heart Failure With Hypertension
Conditions: Heart Failure; Hypertension; Left Ventricle Remodeling; Left Atrial Dilatation Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Sponsor: China National Center for Cardiovascular Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
The Effects and Mechanism of SGLT2 Inhibitors in Stage B of Heart Failure With Hypertension
Conditions: Heart Failure; Hypertension; Left Ventricle Remodeling; Left Atrial Dilatation Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Sponsors: China National Center for Cardiovascular Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Conditions: Type2diabetes; PreDiabetes; Renal Failure Interventions: Drug: Dapagliflozin (Forxiga ®); Drug: Placebo matching Dapaglifolzin; Behavioral: Lifestyle Intervention Sponsors: University Hospital Tuebingen; German Federal Ministry of Education and Research; German Center for Diabetes Research; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI
Condition: Myocardial Infarction Interventions: Drug: Dapagliflozin 10mg Tab; Drug: Placebo Sponsor: Mohammad Hussien Tantawy Soliman Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 24, 2023 Category: Research Source Type: clinical trials
